Cell-Penetrating Peptides (CPPs)

Cell-penetrating peptides have revolutionized intracellular drug delivery by solving the membrane permeability barrier.

Discovery and History

TAT Peptide (1988) - HIV-1 Trans-Activator of Transcription - Found to enter cells and nucleus - First CPP characterized - Sequence: GRKKRRQRRRPPQ

Penetratin (1994) - From Antennapedia homeodomain (Drosophila) - Sequence: RQIKIWFQNRRMKWKK - Established CPP field

Classification of CPPs

By Charge

• Rich in Arg and Lys
• Examples: TAT, R8, R9 (polyarginine)
• Interact with membrane proteoglycans
• Most common class

• Hydrophobic + charged regions
• Examples: Penetratin, Transportan
• Can partition into membranes

• Primarily nonpolar
• Examples: Signal peptide-derived
• Less common, require modification

By Origin

Mechanisms of Entry

Direct Translocation - CPP directly crosses membrane - Transient pore formation - Energy-independent - Occurs at high concentrations

Endocytosis - CPP internalized via vesicles - Energy-dependent - Multiple pathways: - Macropinocytosis (most common) - Clathrin-mediated - Caveolin-mediated

The Arginine Paradox Why polyarginine works: - Arginine guanidinium group - Forms bidentate hydrogen bonds - Interacts with phosphate headgroups - Creates transient membrane defects

Cargo Delivery

What CPPs Can Deliver

Attachment Strategies

• Disulfide bonds (cleavable)
• Maleimide chemistry
• Click chemistry
• Genetic fusion

• Electrostatic complexation (nucleic acids)
• Hydrophobic interaction
• Streptavidin-biotin

Challenges and Solutions

Endosomal Escape **Problem:** Most cargo trapped in endosomes **Solutions:** - Histidine-rich sequences (buffer) - Membrane-lytic peptides - Photochemical internalization - pH-responsive design

Cell Type Selectivity **Problem:** CPPs enter all cells **Solutions:** - Targeting ligands - Activatable CPPs - Cell-specific proteases

Toxicity **Problem:** Membrane disruption at high doses **Solutions:** - Lower concentrations - Transient exposure - Design optimization

Clinical Development

Current Status - Several CPP-drug conjugates in trials - No FDA-approved CPP drugs yet - Active area of research

Examples in Development

• Eteplirsen (Exondys 51) uses cell-penetrating morpholino
• Approved for Duchenne muscular dystrophy

• p28 (tumor suppressor peptide)
• Phase 1 for cancer

Applications

Research Tools - Intracellular protein delivery - CRISPR/Cas9 delivery - Live cell imaging probes

Therapeutic Potential - Cancer (pro-apoptotic peptides) - Genetic diseases (splice correction) - Neurological (crossing blood-brain barrier) - Vaccines (antigen delivery)